We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Medica 2024 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Roche Introduces Upcoming Cobas Pure and Cobas Pro Integrated Solutions at AACC Clinical Lab Expo

By LabMedica International staff writers
Posted on 28 Sep 2021

Roche Diagnostics (Basel, Switzerland) introduced the upcoming cobas Pure and cobas Pro integrated solutions at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo.

The global laboratory community came together for the event held at the Georgia World Congress Center in Atlanta, September 26-30.


Image: cobas e 402 analytical unit (Photo courtesy of Roche Diagnostics)
Image: cobas e 402 analytical unit (Photo courtesy of Roche Diagnostics)

Roche’s future offering of the cobas pure integrated solutions introduced at ACC 2021 is designed for the low-mid volume segment as a main analyzer in small independent labs or lab networks, dedicated analyzer for specific panels, STAT analyzer or back up analyzer. It is designed to provide fast turnaround time and simplified operations. The smart concept of self-operating maintenance executes tasks automatically in the background to support a reduction in the manual burden of daily maintenance. The new reagent carrier will require no operator preparation and will provide up to six months of onboard stability for chemistry and up to four months of onboard stability for immunoassay. The cobas pure integrated solution continues Hitachi’s legacy of reliable systems, which enables smooth workflows and fewer unplanned interruptions. The cobas pure integrated solutions is currently in development.

In addition, Roche introduced the cobas pro integrated solutions with new high throughput configurations to increase testing efficiency. This offering for medium-to-high-volume chemistry and immunoassay testing, features a modular design to offer labs greater flexibility to ramp up their testing capacity to adapt to evolving testing needs

Roche also highlighted the cobas 8100 automated workflow series that delivers automation without compromise through customized workflows. The cobas 8100 automated workflow series is a powerhouse that enables a flexible and fully automated workflow, allowing labs to optimize resources while simultaneously boosting output and quality of results. The cobas 8100 delivers short and predictable time to results across multiple disciplines. It features STAT sample prioritization, intelligent tube transport, upfront sample integrity checks, and an innovative automatic centrifuge module for faster cycle times. In addition to featuring a modular design, the workflow your way concept enables labs to choose workflows using primary, aliquot and mixed sample workflows.

Roche exhibited its cobas connection modules (CCM) featuring STAT prioritization and sample integrity checks, that deliver reliable results run after run. Its innovative design leverages dynamic workflows to reduce bottlenecks, decrease time to results and impact patient care. It offers high throughput transportation of up to 10,000 tests per hour and the flexibility to connect across multiple disciplines. Other products displayed at the event by Roche included the FDA-cleared high-sensitive Elecsys Troponin T Gen 5 STAT to aid in the diagnosis of myocardial infarction (MI). TnT Gen 5 enables clinicians to more quickly diagnose patients with suspected MIs, delivering industry leading turnaround time results in only nine minutes.

Related Links:
Roche Diagnostics 


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
17 Beta-Estradiol Assay
17 Beta-Estradiol Assay
New
Histamine ELISA
Histamine ELISA

Latest AACC 2021 News

Study Showing Differing COVID-19 Antibody Profiles Among Vaccinated and Naturally Infected Individuals Presented at AACC 2021

Study Reveals Varying Antibody Responses and Adverse Reactions Among Recipients of Different COVID-19 Vaccines

Novel Study on Performance of Coronavirus Tests in Children Presented at 2021 AACC Annual Scientific Meeting